Which Is Stronger: Clobetasol or Betamethasone?

Clobetasol propionate is stronger than most formulations of betamethasone. In the United States classification system, clobetasol sits at the very top (Class I, “super-potent”), while betamethasone lands anywhere from Class I to Class V depending on its specific ester form and the vehicle it comes in. That range is the key detail most people miss: “betamethasone” is not one product but a family of formulations, and some of them come remarkably close to clobetasol while others are far milder.

How Potency Is Ranked in the First Place

The strength of a topical steroid is not determined by how much active ingredient is in the tube. It is measured by something called the vasoconstrictor assay, sometimes referred to as the blanching test. When you apply a corticosteroid to normal skin, it constricts the tiny blood vessels underneath, causing a visible whitening or “blanching.” The degree and duration of that blanching response is used to rank one steroid against another, and this test forms the basis for both drug development and regulatory decisions about potency.¹ It is a surprisingly simple concept: more blanching means more potent.

Where things get confusing is that different countries use different classification schemes to group steroids based on those blanching results. The US system uses seven classes, with Class I being the strongest and Class VII the weakest. The UK and many other countries use a four-category system running from “mild” to “very potent.” A recent comparison of these systems found that while the broad groupings often agree, the same steroid can land in different categories depending on which system you use.² This means that when you read “high potency” on a medical website without knowing which country’s system is being referenced, the label could correspond to different absolute strengths.

Where Clobetasol and Betamethasone Sit on the Potency Ladder

Clobetasol propionate 0.05% is the standard bearer for “super-potent.” In every major classification system worldwide, it occupies the top tier. It produces one of the strongest blanching responses of any commercially available topical corticosteroid, and it is typically reserved for stubborn skin conditions that have not responded to milder treatments.

Betamethasone is a different story because it exists as multiple esters, each with different potency. The two main forms you will encounter are betamethasone valerate and betamethasone dipropionate. Betamethasone valerate 0.1% cream is a mid-range steroid, usually categorized as “potent” in UK terms or around Class III to V in the US system, depending on the formulation. Betamethasone dipropionate 0.05% is stronger, and in an optimized or “augmented” vehicle, it reaches Class I in the US system, putting it in the same tier as clobetasol.³ That is the formulation most likely to cause confusion when people compare the two drugs, because augmented betamethasone dipropionate really is in the same potency neighborhood as clobetasol.

Why the Vehicle Changes Everything

The cream, ointment, lotion, or foam a steroid is mixed into is not just a matter of cosmetic preference. It fundamentally changes how much drug penetrates the skin. Ointments occlude the skin surface, trapping moisture and pushing the drug deeper, which is why the same concentration of betamethasone dipropionate in an ointment is more potent than the same drug in a cream. When it is delivered in a specially optimized vehicle, the potency jumps again.³

Clobetasol is also affected by its vehicle, though the range is narrower because it already starts at the top. Clobetasol is available as a cream, ointment, solution, foam, spray, and shampoo. Some of these formats penetrate more efficiently than others, but all clobetasol formulations remain in the super-potent category. The practical lesson: if your doctor switches you from a clobetasol ointment to a betamethasone dipropionate cream, the drop in potency may be larger than you would guess from the drug names alone, because you are moving down in both the active ingredient hierarchy and the vehicle hierarchy at the same time.

Head-to-Head Trials in Psoriasis

Psoriasis is the condition where clobetasol and betamethasone have been most directly compared. The results depend on which betamethasone formulation was tested and what the researchers were measuring.

In a split-body trial comparing clobetasol propionate 0.05% ointment against augmented betamethasone dipropionate 0.05% ointment for psoriasis, significantly more patients showed greater improvement on the side treated with clobetasol. Perhaps more telling, remissions lasted longer after clobetasol use even two weeks after treatment ended.⁴ This is a comparison between two Class I steroids, and clobetasol still came out ahead, suggesting it has a genuine potency edge even within the super-potent tier.

A different trial looked at scalp psoriasis specifically, comparing augmented betamethasone dipropionate lotion against clobetasol propionate solution. Here, the augmented betamethasone lotion actually produced faster early improvement in scaling and induration, with better results at days four and eight. By the end of the study, however, both treatments brought patients to a similar mild-disease endpoint.⁵ The faster onset with betamethasone in this case likely had to do with the lotion vehicle being better suited to the scalp than the clobetasol solution, rather than betamethasone being inherently more potent. Vehicle and body site interacted in a way that muddied the pure potency comparison.

Taken together, these trials paint a picture where clobetasol has a slight but real potency advantage over even augmented betamethasone dipropionate in the same vehicle type, but the vehicle can partially close or even reverse the gap in specific situations.

The Systemic Absorption Problem

Stronger is not always better, and the main reason doctors do not simply prescribe clobetasol for everything is systemic absorption. A topical steroid applied to the skin does not just stay on the surface. Some of it reaches the bloodstream, and from there it can affect the body’s own cortisol production through a feedback loop involving the adrenal glands. This effect is more pronounced with higher-potency steroids, and clobetasol is the poster child for this risk.

Even a single application of 20 to 30 grams of clobetasol propionate 0.05% has been shown to reach detectable blood levels and suppress adrenal gland function in patients with severe atopic dermatitis.⁶ Even more concerning, case reports have documented adrenal failure in patients using well below the amounts traditionally considered dangerous. In one report, patients who used as little as 7.5 grams per week of clobetasol propionate cream over a prolonged period developed adrenal insufficiency that lasted up to four months after stopping the treatment.⁷

Betamethasone dipropionate can also cause adrenal suppression, particularly in its augmented forms, but the risk is generally considered lower at equivalent application amounts because it is slightly less potent. The difference matters most when the treatment area is large, the skin is thin or broken (which increases absorption), or the patient is expected to use the steroid for more than a couple of weeks.

Where on the Body You Apply Matters

Skin absorption varies dramatically by location. The eyelids, groin, and armpits absorb topical steroids at many times the rate of the forearms or shins. This is why you will almost never see clobetasol prescribed for the face, genitals, or skin folds, regardless of the condition being treated. Betamethasone valerate or even lower-potency steroids are preferred for these areas because the enhanced absorption from the thin skin effectively boosts the drug’s local potency without the systemic risks of starting with a super-potent molecule.

The scalp is an interesting exception. Despite having thick skin, the scalp has a rich blood supply and hair follicles that create pathways for absorption. Both clobetasol and betamethasone are commonly used on the scalp for conditions like psoriasis, and the head-to-head trial discussed earlier showed both can be effective there. The choice between them on the scalp often comes down to vehicle preference: many patients find solutions, foams, and lotions more practical than ointments in hair-bearing areas.

Considerations for Children

Parents are understandably cautious about putting potent steroids on their child’s skin, and pediatric guidelines reflect that caution. Children have a higher surface-area-to-body-weight ratio, meaning that the same amount of steroid applied to a child produces proportionally more systemic exposure than in an adult. However, the fear of topical steroids in children has sometimes led to undertreatment, leaving conditions like eczema poorly controlled.

A modeling study on clobetasol use in children with atopic dermatitis found that clobetasol propionate could be applied to up to about 20% of a child’s body surface area (in children older than one year) without causing meaningful changes to circulating cortisol levels. The same study found that short-term clobetasol use did not affect growth velocity, a worry that often comes up with oral steroids but appears less relevant for topical ones used briefly.⁸ That said, clobetasol is still not a first-line choice in pediatric practice. Most dermatologists will try betamethasone valerate or an even milder steroid first and escalate to clobetasol only when lower-potency options fail.

Steroid Withdrawal and the Rebound Problem

A topic that comes up frequently in online skin-care communities is topical steroid withdrawal, sometimes called “topical steroid addiction.” This refers to a rebound flare of skin symptoms, often worse than the original condition, after discontinuing prolonged use of mid-to-high-potency topical steroids.⁹ Clobetasol, as the most potent topical steroid available, is implicated in many of these reports, though withdrawal can occur with prolonged use of any mid-strength-or-above steroid, including betamethasone formulations.

The risk rises with duration and potency. Using clobetasol daily for months, particularly on the face or genitals where it is absorbed readily, creates a scenario where the skin becomes dependent on the anti-inflammatory effects and flares badly when the drug is withdrawn. This is one reason prescriptions for clobetasol often come with a two-week limit on continuous use, with instructions to taper down to a less potent steroid rather than stopping abruptly. Betamethasone dipropionate is sometimes used as that step-down agent, serving as a bridge between clobetasol and milder treatments.

Combination and Sequential Therapy Strategies

Because prolonged clobetasol use carries real risks, dermatologists often use it as a short burst to get a flare under control and then switch to something else for maintenance. One well-studied approach in psoriasis pairs an initial two-week course of clobetasol with a non-steroidal agent called calcipotriol (a vitamin D analog). In a trial testing this sequence, the clobetasol phase produced a significantly larger drop in symptom scores than calcipotriol alone, and when patients transitioned to calcipotriol for the next four weeks, the gains from the clobetasol induction phase were maintained with no rebound.¹⁰

This kind of sequential thinking reflects how clinicians actually use the clobetasol-versus-betamethasone distinction in practice. It is not simply about picking the strongest drug. Clobetasol is the heavier hammer brought in for acute, resistant, or thick-plaque disease, used for a defined period. Betamethasone dipropionate fills a role as either a primary treatment for moderately severe disease or as a step-down from clobetasol. Betamethasone valerate, being milder still, handles ongoing maintenance or treatment of sensitive areas. The potency ladder is not about choosing one drug over another permanently; it is about knowing where each drug fits in a treatment arc.

When Betamethasone Might Actually Be the Better Choice

A common misconception is that stronger always means more effective. In reality, prescribing the most potent steroid available for every skin complaint would cause more harm than good. There are several situations where betamethasone is genuinely preferable to clobetasol, and not just as a consolation prize.

Thin-skinned areas like the face, neck, and inner arms are better served by betamethasone valerate or even lower-potency options. Conditions that require treatment lasting more than two weeks continuously are poor candidates for clobetasol because of the accumulating systemic risk. Mild-to-moderate eczema or dermatitis, which represents the majority of cases seen in primary care, responds perfectly well to mid-potency steroids and does not need the additional firepower. And for patients with large affected areas, the sheer volume of steroid needed to cover the skin makes a less potent agent safer. Twenty percent of body surface area covered in clobetasol raises a very different systemic absorption profile than the same area treated with betamethasone valerate.

There is also the question of patient adherence. Some clobetasol formulations are greasier or more cumbersome to apply, particularly in hair-bearing areas or on the hands. If a patient dislikes their medication enough to skip applications, a slightly less potent but more cosmetically elegant betamethasone product that gets used consistently will outperform a super-potent product sitting unused in the medicine cabinet.

How Blanching Tests Can Be Misleading

The blanching assay is useful for ranking steroids against each other, but it measures vasoconstriction in normal skin on the forearm of healthy volunteers. Diseased skin behaves differently. Psoriatic plaques are thick and poorly permeable, meaning that the relative potency difference between two steroids measured on normal skin may not translate directly to a clinical difference on a plaque. Inflamed, broken skin from eczema absorbs steroids more readily than healthy skin, which can amplify the effective potency of whatever is applied. Even something as simple as the position of the limb during the test can affect the blanching result.¹¹

The real-world gap between clobetasol and betamethasone dipropionate in an augmented vehicle is probably smaller than their blanching-assay rankings suggest, because both are already so far up the potency curve that the incremental difference matters less clinically than factors like vehicle, application frequency, skin condition, and body site. Where the gap becomes unmistakable is between clobetasol and the lower-tier betamethasone formulations, like betamethasone valerate cream, where you are genuinely comparing a super-potent steroid to a moderate one.